Autoantibody against WD repeat domain 1 is a novel serological biomarker for screening of thyroid neoplasia

Abstract

Anti-WDR1 antibody could be a novel approach for serological screening of PTC and UTC, and could be an efficient and inexpensive biomarker.

Survey of autoantibody responses against tumor-associated antigens in thyroid cancer

“…Three of these antigens reacted specifically with sera from patients with thyroid cancer, however the frequency of responses ranged from 4 to 8% thus also showing that cancer-specific autoantibodies in thyroid cancer are relatively rare. On the contrary, Izawa et al [16] identified two ubiquitously expressed antigens -WDR1 and fibronectin 1 and demonstrated that anti-WDR1 autoantibody alone could discriminate between thyroid cancers vs benign nodules and healthy controls with sensitivity of 96.7% and specificity of 91.9% [16]. However, this study was based on a small sample set and the diagnostic value of anti-WDR1 autoantibody must be validated in a larger, independent cohort.…”

Novel TG‐FGFR1 and TRIM33‐NTRK1 transcript fusions in papillary thyroid carcinoma

“…WDR1 plays a crucial role in cytokinesis and cell migration and may be important in the ability of cancer cells to proliferate and invade surrounding tissues . Overexpression of WDR1 was reported in different cancers, including breast cancer, ovarian carcinoma, and thyroid neoplasia …”

“…37,38 Overexpression of WDR1 was reported in different cancers, including breast cancer, ovarian carcinoma, and thyroid neoplasia. [39][40][41] The fusion transcript ZSWIM5-TP53BP2 is made of zinc finger SWIM-type containing 5 gene (ZSWIM5) and tumor protein TP53 binding protein 2 (TP53BP2, also known as ASPP2 Tumor suppressor activity of ARID1B has been demonstrated in vitro in pancreatic cancer cells. 44 Moreover, deletions and mutations of this gene have been reported in hepatocellular carcinoma, childhood neuroblastoma, PTC, and other types of cancer.…”

Serum Immunoproteomics Combined With Pathological Reassessment of Surgical Specimens Identifies TCP-1ζ Autoantibody as a Potential Biomarker in Thyroid Neoplasia

“…However, autoantigenic repertoires of many human neoplasms, eg, endocrine tumors, have not been studied in sufficient detail. Only two top-down studies identified several antigens eliciting autoantibody responses in anaplastic (25) and papillary (26) thyroid carcinomas, and few additional antigens were implicated in thyroid carcinomas in bottom-up setting (15,(27)(28)(29)(30). Importantly, none of these studies focused on encapsulated follicular-patterned lesions.…”